Active Stocks: Zosano Pharma Corporation (NASDAQ:ZSAN), Groupon, Inc. (NASDAQ:GRPN), International Business Machines Corporation (NYSE:IBM), Navigant Consulting Inc. (NYSE:NCI), Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)

Zosano Pharma Corporation (NASDAQ:ZSAN) belongs to Healthcare sector. Its weekly performance is 11.11%. On last trading day company shares ended up $9.00. Zosano Pharma Corporation (NASDAQ:ZSAN) distance from 50-day simple moving average (SMA50) is 7.44%. On 6 July, Zosano Pharma Corporation (NASDAQ:ZSAN) announced that Novo Nordisk (NVO) has notified Zosano of its intention to discontinue the collaboration agreement related to development of a transdermal presentation of select NVO glucagon-like peptide-1 (GLP-1) analogues. Zosano has been notified that the decision relates to a strategic prioritization of NVO’s research portfolio despite continued progress during the collaboration period.

Groupon, Inc. (NASDAQ:GRPN) shares moved up 5.37% in last trading session and ended the day at $5.10. GRPN Gross Margin is 47.40% and its return on assets is -2.30%. Groupon, Inc. (NASDAQ:GRPN) quarterly performance is -29.66%. Groupon, Inc. (NASDAQ:GRPN) said that, it increased the most in five months at Macquarie Capital USA Inc. raised his rating on the shares

International Business Machines Corporation (NYSE:IBM) shares moved up 1.46% in last trading session and ended the day at $169.38. IBM Gross Margin is 50.20% and its return on assets is 12.10%. International Business Machines Corporation (NYSE:IBM) quarterly performance is 5.10%.On 9 July, International Business Machines Corporation (NYSE:IBM) said that, it has produced the first-ever 7-nanometer computer chips.

Navigant Consulting Inc. (NYSE:NCI) ended the last trading day at $14.80. Company weekly volatility is calculated as 1.72% and price to cash ratio as 356.98. Navigant Consulting Inc. (NYSE:NCI) showed a weekly performance of 0.34%.Navigant Consulting Inc. (NYSE:NCI) was downgraded by Zacks from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares moved up 6.34% in last trading session and ended the day at $13.41. DRNA return on assets is -57.10%. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) quarterly performance is -28.14%.On 1 July, Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced that, the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 115,500 shares of common stock to four new employees, with all four grants having a grant date of June 30, 2015 (the “Q2 2015 Inducement Grants”).

Leave a Reply

Your email address will not be published. Required fields are marked *